Poland· PL-100096540
Castagnus
A prolactine inhibitors product containing agni casti fructus extractum siccum, registered in Poland by Wrocławskie Zakłady Zielarskie "Herbapol" S.A..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Agni casti fructus extractum siccum
- Manufacturer
- Wrocławskie Zakłady Zielarskie "Herbapol" S.A.
- Country
- Poland (PL)
- ATC code
- G02CB
- ATC class
- Prolactine inhibitors
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909990826919
- gtin05909990826926
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under G02CB
Prolactine inhibitors, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0b77a2a5-d747-42f0-875d-b923867e4569 GET /v1/drugs/0b77a2a5-d747-42f0-875d-b923867e4569?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "45 mg",
"packaging": "05909990826919 ¦ OTC ¦ Skasowane ¦ 16122\n30 tabl. (1x30)\n05909990826926 ¦ OTC ¦ 16123\n30 tabl.",
"substance": "Agni casti fructi extractum siccum ethanolicum 45 mg",
"common_name": "Agni casti fructus extractum siccum",
"pl_product_id": "100096540",
"pozwolenie_nr": "08269",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about agni casti fructus extractum siccum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.